- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Richard J. Willke on the Value of Real-World Data for Health Plans
According to Richard J. Willke, PhD, chief science officer of ISPOR, real-world data has some unique advantages over randomized clinical trial findings, especially for health plans looking to make coverage decisions.
According to Richard J. Willke, PhD, chief science officer of ISPOR, real-world data has some unique advantages over randomized clinical trial findings, especially for health plans looking to make coverage decisions.
Transcript (slightly modified)
In what ways can real-world data provide better information for decision making than classical clinical trials?
I would say real-world data should be viewed as complimentary to randomized clinical trial, or RCT, data. RCT data are still the gold standard for determining treatment safety and efficacy of course, but we also know that they’re typically performed in restricted settings and restricted populations, which probably aren’t like the health plan characteristics. So the health plans want to track how the treatment really does in its own population.
One of the first things it looks at is often at adherence, because it’s easy to measure, and then analyze the association with outcomes and probably medical costs. It can also look treatments of populations, 1 treatment versus other comparators, things that were never studied in randomized clinical trials. Now, this has to be done carefully, because the real-world data weren’t randomized, so good methodology is really important. But if it’s done carefully, it can aid health plans in decision making about utilization management, step audits, co-pays, prior authorization: the kind of things that help the health plan optimize one treatment as it fits with other treatments.
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
